Accuray Incorporated (ARAY): Earnings growth forecast for next year
Accuray Incorporated (ARAY) relies on software upgrades for its Radixact and CyberKnife systems. Consensus earnings expectations for the n+1 period visualize these trends, where 0.00 serves as the current metric level. Growth is driven by equipment expansion in emerging regions and the implementation of adaptive planning. The company's potential is based on the development of AI algorithms for ultra-precise, real-time monitoring of neoplasms.
Analytical breakdowns and data insights for company accuray.com (ARAY)
- share price and consensus valuation forecast:
- stock exchange capitalization data:
- book capitalization indicators:
- debt and liquidity details:
Total Debt to Equity Ratio Accuray Incorporated|ARAY - Long-Term Debt to Capital|Short-Term Debt to Equity Accuray|ARAY - Aggregate Debt Obligations|Debts to Book Capitalization Accuray Incorporated|ARAY - Company Long-Term Debts|Company Current Liabilities Accuray Incorporated|Quick Liquidity Indicator accuray.com
- earnings and valuation multiples information:
ARAY - Final Profit|Projected Future Earnings Accuray Incorporated|ARAY - Business Payback Period|Future Price to Earnings Accuray Incorporated|ARAY - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Accuray Incorporated|ARAY - Operating profit before deduction of amortization|Earnings per share for the last twelve months Accuray Incorporated|ARAY - Net earnings per one share for the last twelve months|Year-over-year earnings per share growth for the last twelve months accuray.com|ARAY - Earnings per share increase in current year|Net earnings per share growth forecast for next year Accuray Incorporated
Fundamental company valuation:Accuray Inc., ARAY
This indicator reflects the consensus forecast of investment houses regarding the net earnings per share trend for the coming year. On the GURU.Markets platform, the projected change in earnings per share for next year visualizes the shift in market expectations concerning business growth rates. This metric measures the potential for capitalization growth through future operational efficiency. For Accuray Incorporated (ARAY), this trend critically depends on management's ability to balance global sales with costly R&D developments.
Main competitors
ONC (BeiGene Corp) - Earnings growth forecast for next year|Expected net earnings per share growth next year Halozyme Corp HALO|Earnings growth forecast for next year RVMD|Earnings growth forecast for next year ascentage.com (AAPG)|Earnings growth forecast for next year CGON (CG Oncology)|URGN - Expected earnings per share growth for next year|Bicara Bio - Earnings growth forecast for next year|Personalis Genomics (PSNL) - Expected earnings per share growth for next year|ERAS (Erasca, Inc.) - Expected earnings per share growth for next year|delcath.com (DCTH) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year Y-mAbs Therapeutics, Inc.|AURA: Expected earnings per share trend next year|Earnings growth forecast for next year CADL|Earnings growth forecast for next year sellaslifesciences.com (SLS)|Actuate Therapeutics, Inc. - Expected earnings per share growth for next year|citiusonc.com (CTOR) - Expected net earnings per share growth next year|HURA: Expected earnings per share growth for next year|Expected earnings per share trend next year TARA (Protara Therapeutics Inc)|FATE: Earnings growth forecast for next year|WHWK - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year TScan Therapeutics Inc|Projected earnings per share growth rate for next year CSBR (Champions Oncology Corp)|Earnings growth forecast for next year XBIT|Expected earnings per share growth for next year cel-sci.com CVM|Net earnings per share growth forecast for next year OS Therapies Inc OSTX|radiopharmtheranostics.com (RADX) - Expected net earnings per share growth next year|ARTV - Net earnings per share growth forecast for next year|Expected earnings per share trend next year ANL (Adlai Nortye Ltd.)|Veru (VERU) - Net earnings per share growth forecast for next year|Net earnings per share change forecast for next year TPST (Tempest Therapeutics Inc)|Net earnings per share growth forecast for next year Xilio Therapeutics Inc|Expected net earnings per share growth next year Enochian BioSciences RENB|Net earnings per share growth forecast for next year Mural Oncology plc (MURA)|KAPA (kairospharma.com) - Expected earnings per share trend next year|Earnings growth forecast for next year OKUR (OnKure Therapeutics)|Earnings growth forecast for next year CytoMed Therapeutics Ltd GDTC|CRIS: Expected earnings per share growth for next year|Apollomics, Inc. - Projected earnings per share increase next year|THAR: Earnings growth forecast for next year|Expected net earnings per share growth next year Advanced Biomed (ADVB)|GNPX (Genprex) - Earnings growth forecast for next year|Projected earnings per share growth rate for next year CLDI (Calidi Bio)|Earnings growth forecast for next year SBFM|Earnings growth forecast for next year xeneticbio.com (XBIO)|Net earnings per share growth forecast for next year Salarius Pharmaceuticals SLRX|Expected earnings per share trend next year PPBT|AON - Earnings growth forecast for next year|BGNE - Earnings growth forecast for next year|CKPT (Checkpoint Therapeutics, Inc) - Expected earnings per share growth for next year|Expected net earnings per share growth next year elevationoncology.com (ELEV)|ICAD (iCAD Inc.) - Earnings growth forecast for next year|Expected earnings per share growth for next year Ikena (IKNA)|Earnings growth forecast for next year NTBL|Earnings growth forecast for next year viracta.com (VIRX)|Net earnings per share growth forecast for next year MorphoSys Corp MOR|NAYA: Projected earnings per share growth rate for next year|Ascentage Pharma Group - Earnings growth forecast for next year
